Factors associated with sex differences in viral non-suppression in the Swedish InfCareHIV cohort: An observational real-world study.
HIV
PROMs
viral non-suppression
women
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
09 Jan 2024
09 Jan 2024
Historique:
received:
15
09
2023
accepted:
16
12
2023
medline:
10
1
2024
pubmed:
10
1
2024
entrez:
10
1
2024
Statut:
aheadofprint
Résumé
Women living with HIV are underrepresented in clinical trials assessing outcomes of antiretroviral treatment (ART), justifying the need for observational studies. We investigated differences in viral non-suppression between women and men in the Swedish InfCareHIV cohort and analysed results in relation to biological and socio-demographic variables and patient-reported outcome measures (PROMs). The study included people living with HIV (PLWH) aged ≥18 years, who initiated ART at least 6 months prior to inclusion. Data from the InfCareHIV registry 2011-2018 were collected. Associations between variables and HIV RNA ≥50 copies/mL were investigated in uni- and multivariable analyses using generalized estimating equations, providing relative risks (RRs) as effect size. The study included 38% (n = 2981) women. Women were more likely to have HIV RNA ≥50 copies/mL than were men [RR = 1.20, 95% confidence interval (CI): 1.10-1.31]. After adjusting for origin and route of transmission, sex at birth was no longer associated with viral non-suppression. PROMs were available in 52.4% of PLWH, and items associated with viral non-suppression were impaired adherence in women (RR = 2.38, 95% CI: 1.79-3.17) and men (RR 1.84, 95% CI: 1.40-2.42), and experience of side effects in women (RR = 1.49, 95% CI: 1.10-2.02). This observational study found a 20% higher relative risk of viral non-suppression in women than in men and the difference was associated with socio-demographic factors. The associations between PROMs and viral non-suppression varied between women and men. PROMs are important health outcomes that may identify PLWH in need of support to achieve viral non-suppression.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Research, Education and Innovation, Södra Älvsborg Hospital, Borås, Sweden
Organisme : Swedish Physicians Against AIDS Research Foundation
ID : FOb2021-0006
Organisme : Alice Swenzon's Foundation for Scientific Research, Research Council Södra Älvsborg
Organisme : Swedish State Support for Clinical Research
ID : ALFGBG-776271
Informations de copyright
© 2024 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
UNAIDS. Global HIV and AIDS Statistics - Fact Sheet. 2023.
Andany N, Walmsley SL. What's new for antiretroviral treatment in women with HIV. J Virus Erad. 2016;2(2):67-77.
Soon GG, Min M, Struble KA, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS. 2012;26(8):444-453.
Nicastri E, Leone S, Angeletti C, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother. 2007;60(4):724-732.
Thorsteinsson K, Ladelund S, Jensen-Fangel S, et al. Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study. BMC Infect Dis. 2012;12:293.
Rosin C, Elzi L, Thurnheer C, et al. Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV cohort study. HIV Med. 2015;16(5):319-325.
Kipp W, Alibhai A, Saunders LD, et al. Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda. AIDS Care. 2010;22(3):271-278.
Mosha F, Muchunguzi V, Matee M, et al. Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. BMC Public Health. 2013;13:38.
Saunders P, Goodman AL, Smith CJ, et al. Does gender or mode of HIV acquisition affect virological response to modern antiretroviral therapy (ART)? HIV Med. 2016;17(1):18-27.
Andronescu L, Zulu PM, Jackson SS, Hachaambwa L, Claassen CW, Stafford KA. The association between gender and HIV viral suppression on third-line therapy in Zambia: a retrospective cohort study. Int J STD AIDS. 2019;30(5):453-459.
Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis. 2014;209(Suppl 3):S86-S92.
Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med. 2003;11(2):55-59.
Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007;4(2):106-119.
Labisi TO, Podany AT, Fadul NA, Coleman JD, King KM. Factors associated with viral suppression among cisgender women living with human immunodeficiency virus in the United States: an integrative review. Womens Health (Lond). 2022;18:1-13.
Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011;8(4):277-287.
Katz IT, Ryu AE, Onuegbu AG, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16(3 Suppl 2):18640.
Hatcher AM, Smout EM, Turan JM, Christofides N, Stöckl H. Intimate partner violence and engagement in HIV care and treatment among women: a systematic review and meta-analysis. Aids. 2015;29(16):2183-2194.
Malama K, Logie CH, Sokolovic N, et al. Pathways from HIV-related stigma, racial discrimination, and gender discrimination to HIV treatment outcomes among women living with HIV in Canada: longitudinal cohort findings. J Acquir Immune Defic Syndr. 2023;94(2):116-123.
About InfCareHIV. [cited 2022]. https://infcarehiv.se/about-infcarehiv
Carlander C, Brännström J, Månsson F, et al. Cohort profile: InfCareHIV, a prospective registry-based cohort study of people with diagnosed HIV in Sweden. BMJ Open. 2023;13(3):e069688.
Marrone G, Mellgren Å, Eriksson LE, Svedhem V. High concordance between self-reported adherence, treatment outcome and satisfaction with care using a nine-item health questionnaire in InfCareHIV. PLoS One. 2016;11(6):e0156916.
Fugl-Meyer AR, Melin R, Fugl-Meyer KS. Life satisfaction in 18- to 64-year-old swedes: in relation to gender, age, partner and immigrant status. J Rehabil Med. 2002;34(5):239-246.
WHO. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. 2021.
Brattgård H, Björkman P, Nowak P, Treutiger CJ, Gisslén M, Elvstam O. Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: a Swedish observational study. PLoS One. 2022;17(5):e0268540.
Mujugira A, Celum C, Tappero JW, Ronald A, Mugo N, Baeten JM. Younger age predicts failure to achieve viral suppression and virologic rebound among HIV-1-infected persons in serodiscordant partnerships. AIDS Res Hum Retroviruses. 2016;32(2):148-154.
Sabin CA, Smith CJ, d'Arminio Monforte A, et al. Response to combination antiretroviral therapy: variation by age. Aids. 2008;22(12):1463-1473.
Saracino A, Lorenzini P, Lo Caputo S, et al. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Clin Microbiol Infect. 2016;22(3):288.e1-288.e8.
Geter A, Sutton MY, Armon C, Buchacz K, HIV Outpatient Study Investigators. Disparities in viral suppression and medication adherence among women in the USA, 2011-2016. AIDS Behav. 2019;23(11):3015-3023.
Norcini Pala A, Kempf MC, Konkle-Parker D, et al. Intersectional stigmas are associated with lower viral suppression rates and antiretroviral therapy adherence among women living with HIV. Aids. 2022;36(13):1769-1776.
Bulgiba A, Mohammed UY, Chik Z, Lee C, Peramalah D. How well does self-reported adherence fare compared to therapeutic drug monitoring in HAART? Prev Med. 2013;57(Suppl):S34-S36.
Byrd KK, Hou JG, Hazen R, et al. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr. 2019;82(3):245-251.
Puskas CM, Kaida A, Miller CL, et al. The adherence gap: a longitudinal examination of men's and women's antiretroviral therapy adherence in British Columbia, 2000-2014. Aids. 2017;31(6):827-833.
Meade CM, Badell M, Hackett S, et al. HIV care continuum among postpartum women living with HIV in Atlanta. Infect Dis Obstet Gynecol. 2019;2019:8161495.
Li H, Marley G, Ma W, et al. The role of ARV associated adverse drug reactions in influencing adherence among HIV-infected individuals: a systematic review and qualitative meta-synthesis. AIDS Behav. 2017;21(2):341-351.
Protopopescu C, Raffi F, Roux P, et al. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother. 2009;64(3):599-606.
Phillips T, Cois A, Remien RH, et al. Self-reported side effects and adherence to antiretroviral therapy in HIV-infected pregnant women under option B+: a prospective study. PLoS One. 2016;11(10):e0163079.
Mellgren Å, Eriksson LE, Reinius M, Marrone G, Svedhem V. Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study. PLoS One. 2020;15(12):e0242710.
D'Arminio Monforte A, Tavelli A, Sala M, et al. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study. J Antimicrob Chemother. 2023;78(4):933-945.
Garriga C, Gutiérrez Trujillo L, del Romero J, et al. Psychological distress in women and men living with HIV in Spain: a cross-sectional telephone survey. Evid Based Ment Health. 2020;23(3):91-99.
Crockett KB, Entler KJ, Brodie E, et al. Brief report: linking depressive symptoms to viral nonsuppression among women with HIV through adherence self-efficacy and ART adherence. J Acquir Immune Defic Syndr. 2020;83(4):340-344.
Moore DM, Zhang W, Yip B, et al. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010;11(5):299-307.
Sörstedt E, Nilsson S, Blaxhult A, et al. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels. BMC Infect Dis. 2016;16:305.
Elvstam O, Marrone G, Medstrand P, et al. All-cause mortality and serious non-AIDS events in adults with low-level human immunodeficiency virus viremia during combination antiretroviral therapy: results from a Swedish Nationwide observational study. Clin Infect Dis. 2021;72(12):2079-2086.
Bontell I, Häggblom A, Bratt G, Albert J, Sönnerborg A. Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011. PLoS One. 2013;8(3):e59337.